Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Marine lipids, particularly omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been studied for their potential benefit in liver health, including hepatitis. The scientific rationale is primarily based on their anti-inflammatory properties. Chronic hepatitis, whether viral (e.g., hepatitis B or C) or non-viral (such as autoimmune hepatitis or non-alcoholic steatohepatitis), often involves persistent liver inflammation that can progress to fibrosis and cirrhosis. Omega-3 fatty acids modulate immune responses and reduce the production of pro-inflammatory cytokines, which may help attenuate liver inflammation.

Some clinical studies and animal models suggest that marine lipids can reduce hepatic fat accumulation and improve liver enzyme profiles in non-alcoholic fatty liver disease (NAFLD), a condition often considered alongside hepatitis in liver health research. However, robust evidence specifically addressing efficacy in viral hepatitis is limited, with most studies being small, short-term, or focused on surrogate endpoints (such as liver enzymes rather than histological improvement or viral clearance). There is also emerging evidence that omega-3 supplementation may help manage complications of chronic liver disease, such as dyslipidemia and cardiovascular risk.

While marine lipids are not standard therapy for hepatitis, their use as an adjunct may have modest benefit, particularly in inflammation-driven liver conditions. Larger, well-designed clinical trials are needed to establish definitive roles. Current evidence supports cautious optimism but does not justify marine lipids as a primary treatment for hepatitis.

More about marine lipid
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by marine lipid

Products containing marine lipid